Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib and Binimetinib in BRAF Mutant Melanoma Brain Metastases
NCT03898908Phase 2Completed
- Start
- Jul 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib in melanoma, brain metastases. Started Jul 2019; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on NCT03898908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03898908.